linjc16/ctgov huggingface dataset:
Effect of Rehabilitation of Patients With a Central Nervous System Lesion

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to analyse the prehensions deficits and the effect of prehension rehabilitation in central nervous system lesioned people

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Other: rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult minimum 6mounth after first stroke Minimal prehension of both hands Exclusion Criteria: Diabetuss Other Upper Limb pathologies MMSE < 26

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rehabilitation<br>Bilateral and unilateral prehension oriented rehabilitation to enhance prehension. | Other: rehabilitation<br>* 4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prehension functionality |  | 4 weeks before, just before, after first part and after the second part of rehabilitation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hand, Rehabilitation
PH-797804 LPS Study in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The study was performed to assess the effect of PH-797804 on neutrophils (white cells) in the sputum after a challenge with an endotoxin (inhaled LPS). Neutrophils are a sign of inflammation and PH-797804 is being developed as a potential anti-inflammatory treatment for patients with Chronic Obstructive Pulmonary Disease (COPD).

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Determine the Effects of a Single Oral Dose of Ph-797804 on Induced Sputum Inflammatory Markers Following Inhaled Lipopolysaccharide (Lps) Challenge in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: PH-797804
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or female (WONCBP), non atopic volunteers aged 18-50 years Able to produce sputum Exclusion Criteria: Current Smokers Abnormal liver function test Respiratory Tract Infection within 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br> | Drug: PH-797804<br>* 30 MG Single dose<br>|
| Placebo Comparator: Arm B<br> | Drug: Placebo<br>* matching placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sputum Cell Counts | Neutrophil & Macrophage count (total and differential) | 6 hours post LPS challenge | 
| Sputum Cytokines | TNF-α, MIP-1β, IL-6, MPO, MCP-1, GRO-α | 6 hours post LPS challenge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic Inflammatory Indices | Neutrophil count, GRO-α, TNF-α, MIP-1β, IL-6, MPO, MCP-1, CRP | 1, 4, 6 and 7 hours post LPS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, LPS
Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out whether a single fecal microbiota transplantation is an effective and safe treatment as an adjunct to standard therapy in patients with ulcerative colitis.

Official Title
-----------------
Single Fecal Microbiota Transplantation Via Colonoscope as an Adjunct Therapy in the Treatment of Ulcerative Colitis

Conditions
-----------------
Ulcerative Colitis

Intervention / Treatment
-----------------
* Other: Fecal microbiota transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: active ulcerative colitis (PUCAI 10-64) in whom fecal microbiota transplantation via colonoscope can be performed Exclusion Criteria: severe ulcerative colitis (PUCAI > 65)

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fecal microbiota transplantation<br>A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment | Other: Fecal microbiota transplantation<br>* A single fecal microbiota transplantation through colonoscope<br>|
| No Intervention: Standard medical treatment<br>Standard medical treatment as recommended by the ECCO Guidelines of UC therapy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Activity of ulcerative colitis | Change from baseline in the Pediatric Ulcerative Colitis Activity Index (PUCAI) at 1 month, 3 months, 6 months, and 12 months. | Within 1 year after the intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colonic inflammation | Change from baseline in the fecal calprotectin at 1 month, 3 months, 6 months, and 12 months. | Within 1 year after the intervention | 
| Colonic inflammation | Endoscopic Mayo score at 3 and 12 months after the intervention | Within 1 year after the intervention | 
| Adverse events |  | Within 1 year after the intervention |
Cytokines and Chemokines in Erythema Migrans

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Official Title
-----------------
Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans

Conditions
-----------------
Erythema Migrans

Intervention / Treatment
-----------------
* Drug: antibiotic treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: erythema migrans in patients > 18 years Exclusion Criteria: pregnancy or lactation taking antibiotic with antiborrelial activity within 10 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: erythema migrans patients treated with antibiotics<br>adult patients with erythema migrans will be treated with oral antibiotics | Drug: antibiotic treatment<br>* Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inflammatory proteins in erythema migrans patients | The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses in serum and if available, skin, of patients during active infection and after treatment. | up to 12 months follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gene polymorphisms in erythema migrans patients | The expression of disease-relevant genomic variants will be assessed using ImmunoChip. | at enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
outcome, erythema migrans, Lyme borreliosis, inflammation
Non-Invasive Determination of Fetal Chromosome Abnormalities

Study Overview
=================
Brief Summary
-----------------
The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18), Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and CVS procedures.

Official Title
-----------------
Non-Invasive Determination of Fetal Chromosome Abnormalities

Conditions
-----------------
Down Syndrome (Trisomy 21), Edward's Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Klinefelter Syndrome (47, XXY), and Other Chromosome, Abnormalities.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This study is only applicable to women who are between 8 and 30 weeks' gestation and who have been determined increased risk for fetal aneuploidy. In the interest of expediting and simplifying this study, the investigators want only women who have already decided to undergo second-trimester amniocentesis or CVS. Exclusion Criteria: The only exclusion criteria are those mentioned.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Air Pollution and Cardiometabolic Study

Study Overview
=================
Brief Summary
-----------------
The study mainly focuse on examining the subjects living in traffic polluted area and assessing the popuation health risk using disease and risk assessment models.

Official Title
-----------------
Characterization and Health Risk Assessment of Exposure to Source-Specific PM2.5 in Subjects in Beijing

Conditions
-----------------
Cardiovascular Outcomes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living in PU community neighborhood，Non smoker and No diseases ,and so on. Exclusion Criteria: Advanced microvascular or neuropathic complications and active cardiovascular disease,and so on.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular endothelial function | Vascular endothelial function measured by Endo-PAT2000 | Four months | 
| Arrythmias | Twenty four-hour electrocardiograms | Four months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| System inflammatory | Analyzed systemic inflammation biomarkers,such as C-reaction Protein and Blood coagulation by ELISA | Four months |
Quantitative and Qualitative MRI Study of Steatosis in Patients With Metabolic Steatopathy

Study Overview
=================
Brief Summary
-----------------
This is a single centre prospective open-label, non-randomised pilot study whose aim is to identify MRI parameters to better evaluate inflammation and liver fibrosis and thus, in the near future, to avoid the need for liver biopsy. To achieve this: The MRI study will be completed by adding two sequences: Measurement of T1 and multiecho T2*. The other data will be extracted from usual sequences. Part of the histological samples will be used for the weighted levels of fat and iron, and for the lipidomic study. Usual blood samples will be completed by samples for the serum library

Official Title
-----------------
Quantitative and Qualitative MRI Study of Steatosis in Patients With Metabolic Steatopathy

Conditions
-----------------
Overweight, Type 2 Diabetes, Obesity

Intervention / Treatment
-----------------
* Other: 2 additional MRI sequences
* Other: An additional blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been informed about the research Patients with national health insurance cover Patients who are overweight (BMI > 25) or have type 2 diabetes suggesting a disturbance of hepatic enzymes (ASAT < 8 times normal values and ALAT > twice normal values) after a complete hepatopathy assessment Obese patients with a hepatic anomaly (steatosis) revealed by imaging or biological assessment (ASAT < 8 times normal values and ALAT > twice normal values) who are eligible for bariatric surgery and a preoperative liver MRI examination. Exclusion Criteria: Non-corrected coagulation disorder. Patients aged over 80 years Patients aged less than 18 years Patients without legal protection Patients with a contra-indication for MRI (Pacemaker, intraocular metallic foreign body, weight>150kg) Patients without national health insurance cover

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients requiring a liver biopsy<br> | Other: 2 additional MRI sequences<br> <br> Other: An additional blood sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine a correlation coefficient > 0.80, alpha 0.05 and beta 0.20 between the MRI markers relevant. |  | Baselines | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the correlation between the unsaturated fat measurements and MRI Lipidomics Spectro analysis. |  | Baselines | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients, present, undergo bariatric surgery
Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40 in Vitrectomy

Study Overview
=================
Brief Summary
-----------------
Total intravenous anesthesia (TIVA) and inhalation anesthesia are both widely and safely used, and there are many clinical trials comparing these on various aspects of anesthesia. However, there have not been studies comparing the quality of recovery from the different methods of general anesthesia in vitrectomy. In this study, the investigators compare the functional recovery after general anesthesia in TIVA and inhalation anesthesia with QoR-40 questionnaire in vitrectomy.

Conditions
-----------------
Vitrectomy Operation Under General Anesthesia

Intervention / Treatment
-----------------
* Drug: fresofol and remifentanil
* Drug: desflurane and remifentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (20-80 years old) scheduled for vitrectomy surgery undergoing general anesthesia. ASA 1-3 Exclusion Criteria: Patients with allergy to anesthetic agents Anticipated difficult airway BMI > 30 kg/m2 Chronic obstructive pulmonary disease Heart failure 6. Unstable angina

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TIVA group<br>Anesthesia is maintained with fresofol and remifentanil | Drug: fresofol and remifentanil<br>* Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.<br>|
| Active Comparator: Des group<br>Anesthesia is maintained with desflurane and remifentanil | Drug: desflurane and remifentanil<br>* Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoR-40 score |  | at 6 hours later after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propofol, desflurane, quality of recovery, vitrectomy
Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.

Study Overview
=================
Brief Summary
-----------------
Patients with inflammatory bowel disease (IBD) suffer from a diminished quality of life compared to healthy adults. This is due to the chronic course of disease accompanied with diarrhea, stomach pains but also with psychological stress. It is known that physical education may improve course of disease and quality of life in a multitude of diseases. These include coronary heart disease, malignancies and also depression. The investigators believe that sport is as effective supportive tool in improving quality of life in IBD patients. But data is lacking with regard to controlled randomized clinical trials. Because of the small amount of data available the investigators considered a feasibility study. Our hypothesis is that IBD patients will cope with moderate exercise. The investigators further suspect that these patients improve their quality of life compared with patients in the control group.

Official Title
-----------------
Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.

Conditions
-----------------
Quality of Life in Patients With Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Behavioral: physical exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years proven colitis ulcerosa (CU) proven crohns disease (CD) diagnosis >= 1 year before start of the study low or moderate disease activity Exclusion Criteria: < 18 years high disease activity regular exercise > 2 hours per week diagnosis of CU oder CD < 1 year before start of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention<br>Patients of the intervention arm receive a 10 week exercise program | Behavioral: physical exercise<br>* 10 weeks physical exercise; three times a week<br>|
| No Intervention: Control<br>Patients of the control arm do not participate in exercise | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  | 10 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease activity |  | 10 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
inflammatory bowel disease, IBD, quality of life, Inflammatory Bowel Disease Questionnaire